Institution Directory

Clinical trials at UPMC (University of Pittsburgh)

Sites in Pittsburgh, PA

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Nov 1, 2026, 3:24 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1600

Shown on this page

Current sort

Live official records

Conditions: Heart Diseases, ASD - Atrial Septal Defect, VSD - Muscular Ventricular Septal Defect, PFO - Patent Foramen Ovale, PIVSD - Post Infarct Muscular Ventricular Septal Defect, Valvular Heart Disease
Interventions: Amplatzer™ Occlusion Devices, Epic™ Surgical Tissue Heart Valve devices; Device
Lead sponsor: Abbott Medical Devices; Industry
Eligibility: Not listed
Enrollment: 2,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2039
U.S. locations: 13
States / cities: Los Angeles, California • Washington D.C., District of Columbia • Miami, Florida + 9 more

Conditions: Down Syndrome, Recurrent B Acute Lymphoblastic Leukemia
Interventions: 3-Dimensional Conformal Radiation Therapy, Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration, Bone Marrow Biopsy, Calaspargase Pegol, Cytarabine, Dexamethasone, Hydrocortisone Sodium Succinate, Lumbar Puncture, Mercaptopurine, Methotrexate, Nivolumab, Pegaspargase, Vincristine Sulfate; Radiation · Drug · Procedure + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 1 Year to 30 Years
Enrollment: 461 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 211
States / cities: Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 151 more

Conditions: Burn Injury, Thermal Burn
Interventions: Plasma, Standard care; Biological
Lead sponsor: Jason Sperry; Other
Eligibility: 18 Years to 75 Years
Enrollment: 750 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Cytokine Release Syndrome
Interventions: CTO1681 10 µg, CTO1681 20 μg, CTO1681 30 μg, CTO1681 10 µg Run-in / 20 µg Treatment, CTO1681 20 µg Run-in / 30 µg Treatment; Drug
Lead sponsor: CytoAgents, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 6
States / cities: Orange, California • Augusta, Georgia • Boston, Massachusetts + 3 more

Conditions: Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
Interventions: Best Practice, Biospecimen Collection, Electronic Health Record Review, Survey Administration, Triptorelin Pamoate; Other · Procedure · Drug
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 39 Years · Female only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 201
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 143 more

Conditions: Stage II Breast Cancer, Stage IIIA Breast Cancer
Interventions: Axillary Lymph Node Dissection (ALND), Nodal Radiation Therapy, Axillary Radiation Therapy; Procedure · Radiation
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 2,012 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2031
U.S. locations: 1228
States / cities: Daphne, Alabama • Mobile, Alabama • Anchorage, Alaska + 730 more

Conditions: Pulmonary Fibrosis
Interventions: Not listed
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2030
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Pulmonary Fibrosis
Interventions: Not listed
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Enrollment: 2,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2035
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: CARDIOMETABOLIC CONDITIONS, Obesity, Pre-diabetes, Metabolic Syndrome, Type2diabetes, Hypertension, Dyslipidemias
Interventions: Base intervention, Augmented Intervention; Behavioral
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 50 Years to 74 Years
Enrollment: 1,029 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 3
States / cities: Chicago, Illinois • St Louis, Missouri • Pittsburgh, Pennsylvania

Conditions: Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Unresectable Breast Carcinoma, Metastatic Breast Carcinoma
Interventions: Atezolizumab, Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Bone Scan, Computed Tomography, Magnetic Resonance Imaging, Olaparib, Positron Emission Tomography, Questionnaire Administration, X-Ray Imaging; Drug · Procedure · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 58
States / cities: Phoenix, Arizona • Scottsdale, Arizona • La Jolla, California + 43 more

Conditions: Extensive Stage Lung Small Cell Cancer
Interventions: Ivonescimab 10 mg/kg, Ivonescimab 20 mg/kg; Drug
Lead sponsor: PrECOG, LLC.; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 13
States / cities: Miami, Florida • Chicago, Illinois • Baltimore, Maryland + 10 more

Conditions: Anemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions: Cyclophosphamide, Fludarabine Phosphate, Ibrutinib, Laboratory Biomarker Analysis, Pharmacogenomic Study, Quality-of-Life Assessment, Rituximab; Drug · Other · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 529 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2026
U.S. locations: 781
States / cities: Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 509 more

About this UPMC (University of Pittsburgh) institution page

What this page lists: ClinicalTrials.gov records that list UPMC (University of Pittsburgh) in Pittsburgh, PA as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status: A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Clinical trials at UPMC (University of Pittsburgh)

Filter and sort this campus

Live official records

Abbott Structural Heart Device Registry

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Plasma Resuscitation Early for Evaluating Volume and Endotheliopathy of Thermal Injury (PREEVEnT) Trial

Study of CTO1681 for the Prevention and Treatment of CRS in Patients Receiving CAR T-Cell Therapy

Triptorelin for the Prevention of Ovarian Damage in Adolescents and Young Adults With Cancer

Comparison of Axillary Lymph Node Dissection With Axillary Radiation for Patients With Node-Positive Breast Cancer Treated With Chemotherapy

Microarray Analysis of Gene Expression in Idiopathic Pulmonary Fibrosis (IPF)

Genetic Polymorphisms in Idiopathic Pulmonary Fibrosis (IPF)

The PIVOT Trial: Project on EHR-Integrated Lifestyle Interventions for Adults Aged Fifty and Older

Testing Olaparib Either Alone or in Combination With Atezolizumab in BRCA Mutant Non-HER2-positive Breast Cancer

Phase II Study of Platinum/Etoposide Plus Ivonescimab for Extensive-Stage Small Cell Lung Cancer

Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

About this UPMC (University of Pittsburgh) institution page